menu
    • menu

    Find Suvorexant manufacturers, exporters & distributors on PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    12

    API Suppliers

    API Suppliers

    3

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    9

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 20,191

    MARKET PLACE

    3

    API

    0

    FDF

    5INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    4

    FDF Dossiers

    FDF Dossiers

    4

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    12

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    15

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    130,017,868

    Annual Reports

    1,441

    Finished Drug Prices

    NA

    146 RELATED EXCIPIENT COMPANIES

    228EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1030377-33-3, Mk-4305, Belsomra, Mk4305, Mk 4305, [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone
    Molecular Formula
    C23H23ClN6O2
    Molecular Weight
    450.9  g/mol
    InChI Key
    JYTNQNCOQXFQPK-MRXNPFEDSA-N
    FDA UNII
    081L192FO9
    Suvorexant
    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
    Suvorexant is an Orexin Receptor Antagonist. The mechanism of action of suvorexant is as an Orexin Receptor Antagonist, and P-Glycoprotein Inhibitor, and Cytochrome P450 3A Inhibitor.
    1 2D Structure

    Suvorexant

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
    2.1.2 InChI
    InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
    2.1.3 InChI Key
    JYTNQNCOQXFQPK-MRXNPFEDSA-N
    2.1.4 Canonical SMILES
    CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
    2.1.5 Isomeric SMILES
    C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    081L192FO9
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

    2. Belsomra

    3. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-

    4. Mk 4305

    5. Mk-4305

    6. Mk4305

    2.3.2 Depositor-Supplied Synonyms

    1. 1030377-33-3

    2. Mk-4305

    3. Belsomra

    4. Mk4305

    5. Mk 4305

    6. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

    7. Suvorexant (mk-4305)

    8. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

    9. Chembl1083659

    10. Chebi:82698

    11. 081l192fo9

    12. ((7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

    13. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-

    14. (r)-(4-(5-chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone.

    15. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone

    16. Suvorexant [usan:inn]

    17. Dora-analogue

    18. Unii-081l192fo9

    19. Belsomra (tn)

    20. Suv

    21. Suvorexant [mi]

    22. Suvorexant [inn]

    23. Suvorexant [jan]

    24. Suvorexant (jan/usan)

    25. Suvorexant [usan]

    26. Suvorexant; Mk 4305

    27. Suvorexant [vandf]

    28. Suvorexant [who-dd]

    29. Amy337

    30. Gtpl2890

    31. Schembl1586289

    32. Suvorexant [orange Book]

    33. Dtxsid90145616

    34. Ex-a211

    35. Belsomra Component Suvorexant

    36. Bdbm50318701

    37. Mfcd22377755

    38. Zinc49036447

    39. Akos022185167

    40. Cs-0614

    41. Db09034

    42. Suvorexant Component Of Belsomra

    43. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

    44. Ac-30276

    45. As-74879

    46. Hy-10807

    47. Bcp0726000197

    48. Ft-0697203

    49. Sw219649-1

    50. D10082

    51. J-690010

    52. Q7650517

    53. Cas:1030377-33-3;mk-4305

    54. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole Mk 4305

    2.4 Create Date
    2008-10-20
    3 Chemical and Physical Properties
    Molecular Weight 450.9 g/mol
    Molecular Formula C23H23ClN6O2
    XLogP34.9
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count3
    Exact Mass450.1571017 g/mol
    Monoisotopic Mass450.1571017 g/mol
    Topological Polar Surface Area80.3 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity664
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Orexin Receptor Antagonists

    Substances that bind to and inhibit the action of OREXIN RECEPTORS. Drugs in this class have been used as SLEEP AIDS, PHARMACEUTICAL. (See all compounds classified as Orexin Receptor Antagonists.)

    Sleep Aids, Pharmaceutical

    Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    SUVOREXANT
    5.2.2 FDA UNII
    081L192FO9
    5.2.3 Pharmacological Classes
    Orexin Receptor Antagonist [EPC]; Orexin Receptor Antagonists [MoA]; P-Glycoprotein Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]
    5.3 ATC Code

    N - Nervous system

    N05 - Psycholeptics

    N05C - Hypnotics and sedatives

    N05CM - Other hypnotics and sedatives

    N05CM19 - Suvorexant

    5.4 Absorption, Distribution and Excretion

    Absorption

    Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%.

    Route of Elimination

    Approximately 66% is eliminated in feces and 23% is eliminated in urine.

    Volume of Distribution

    Mean volume of distribution is approximately 49 litres.

    5.5 Metabolism/Metabolites

    Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity.

    5.6 Biological Half-Life

    Mean half life is approximately 12 hours.

    5.7 Mechanism of Action

    Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666204200,"product":"SUVOREXANT (FORM-II)","address":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"22000","totalValueFC":"21523","currency":"USD","unitRateINR":1771000,"date":"20-Oct-2022","totalValueINR":"1771000","totalValueInUsd":"21523","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"4975024","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692815400,"product":"SUVOREXANT\/ DCO (5 MG)","address":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA","city":"Hyderabad","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.07","actualQuantity":"0.065","unit":"KGS","unitRateFc":"6737.8","totalValueFC":"434.6","currency":"USD","unitRateINR":553845.8953846154,"date":"24-Aug-2023","totalValueINR":"35999.9832","totalValueInUsd":"434.6","indian_port":"HYDERABAD ICD","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703183400,"product":"SUVOREXANT (FORM-II) IN-HOUSE","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"25000","totalValueFC":"6186.7","currency":"USD","unitRateINR":2060000,"date":"22-Dec-2023","totalValueINR":"515000","totalValueInUsd":"6186.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6225788","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705689000,"product":"SUVOREXANT (FORM - II) IN-HOUSE","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"TOWA PHARMACEUTICAL","customerCountry":"JAPAN","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"25000","totalValueFC":"9877.4","currency":"USD","unitRateINR":2052322.5,"date":"20-Jan-2024","totalValueINR":"820929","totalValueInUsd":"9877.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6899362","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""}]
    20-Oct-2022
    20-Jan-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 1030377-33-3 / Suvorexant API manufacturers, exporters & distributors?

    Suvorexant manufacturers, exporters & distributors 1

    21

    PharmaCompass offers a list of Suvorexant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Suvorexant manufacturer or Suvorexant supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Suvorexant manufacturer or Suvorexant supplier.

    PharmaCompass also assists you with knowing the Suvorexant API Price utilized in the formulation of products. Suvorexant API Price is not always fixed or binding as the Suvorexant Price is obtained through a variety of data sources. The Suvorexant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Suvorexant

    Synonyms

    1030377-33-3, Mk-4305, Belsomra, Mk4305, Mk 4305, [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

    Cas Number

    1030377-33-3

    Unique Ingredient Identifier (UNII)

    081L192FO9

    About Suvorexant

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

    Suvorexant Manufacturers

    A Suvorexant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Suvorexant, including repackagers and relabelers. The FDA regulates Suvorexant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Suvorexant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Suvorexant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Suvorexant Suppliers

    A Suvorexant supplier is an individual or a company that provides Suvorexant active pharmaceutical ingredient (API) or Suvorexant finished formulations upon request. The Suvorexant suppliers may include Suvorexant API manufacturers, exporters, distributors and traders.

    click here to find a list of Suvorexant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Suvorexant USDMF

    A Suvorexant DMF (Drug Master File) is a document detailing the whole manufacturing process of Suvorexant active pharmaceutical ingredient (API) in detail. Different forms of Suvorexant DMFs exist exist since differing nations have different regulations, such as Suvorexant USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Suvorexant DMF submitted to regulatory agencies in the US is known as a USDMF. Suvorexant USDMF includes data on Suvorexant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Suvorexant USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Suvorexant suppliers with USDMF on PharmaCompass.

    Suvorexant NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Suvorexant as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Suvorexant API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Suvorexant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Suvorexant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Suvorexant NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Suvorexant suppliers with NDC on PharmaCompass.

    Suvorexant GMP

    Suvorexant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Suvorexant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Suvorexant GMP manufacturer or Suvorexant GMP API supplier for your needs.

    Suvorexant CoA

    A Suvorexant CoA (Certificate of Analysis) is a formal document that attests to Suvorexant's compliance with Suvorexant specifications and serves as a tool for batch-level quality control.

    Suvorexant CoA mostly includes findings from lab analyses of a specific batch. For each Suvorexant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Suvorexant may be tested according to a variety of international standards, such as European Pharmacopoeia (Suvorexant EP), Suvorexant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Suvorexant USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search